Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

June 16, 2016June 16, 2016

PET Imaging for Lung Cancer Helps Monitor Treatment Response

News

Research shows that positron emission tomography (PET) might allow clinicians to better monitor atezolizumab treatments in non-small cell lung cancer (NSCLC) patients. The findings, presented at the recent 2016 Annual Meeting of the Society ... Read more

June 8, 2016June 8, 2016

Biocept Launches PD-L1 Blood Test for Immuno-Oncology Applications

News

Biocept, a molecular diagnostics company focused on liquid biopsies for cancer, recently announced an expansion of its product portfolio with the launch of a blood test for PD-L1 protein expression – ... Read more

June 1, 2016June 1, 2016

Immune Factor Seen to Control T-Cell Checkpoints Involved in Spread of Cancers and Infections

News

Researchers at Sanford-Burnham Prebys Medical Discovery Institute discovered an immune factor regulating T-cell checkpoints. Mice lacking the molecule, called PSGL-1, had more effective immune responses against both infections and cancer ... Read more

May 23, 2016May 23, 2016

New Multiple Myeloma Drug Phase 3 Trial Shows Increased Survival Chance

News

Biotechnology company Genmab recently announced that an interim analysis of its Phase 3 clinical trial of daratumumab (Darzalex), in combination with lenalidomide and dexamethasone for multiple myeloma, met its primary ... Read more

May 11, 2016May 11, 2016

CAR T-cell Trial in People with Advanced Leukemia Reports 90% Complete Remission Rate

News

A clinical trial of CAR T-cell therapy in advanced leukemia patients in China reported a 90 percent complete remission rate. The results, presented by Professor Huang He at the recent ... Read more

May 2, 2016May 2, 2016

Checkpoint Inhibitors Seen to Show Potential of Immunotherapy in Several Cancer Studies

News

Several new checkpoint inhibitors — a class of immunotherapy drugs used in cancer — continue to show beneficial effects in numerous cancer types, according to data presented at the recent American ... Read more

April 27, 2016April 27, 2016

Early Data Shows Success in Immunotherapy Clinicial Trial for Leukemia Patients

News

Early data from a clinical trial of CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) showed a remarkable response rate, providing hope to patients that new treatments ... Read more

April 14, 2016April 14, 2016

Androgen Deprivation Therapies Seen to Counter Immunotherapies in Prostate Cancer

News

Medical androgen deprivation therapies (ADT), the most commonly used medical treatment for prostate cancer, might suppress immune responses, preventing immunotherapies from working. Male sex hormones, or androgens, are crucial for ... Read more

April 1, 2016April 1, 2016

Aduro Biotech to Finance Cancer Immunotherapy and Vaccine Research Initiative at UC Berkeley

News

In a new partnership funded by Aduro Biotech, cancer immunologists and infectious disease specialists at the University of California at Berkeley will work together to develop new cancer immunotherapies and advance vaccine ... Read more

March 30, 2016March 31, 2016

Skin Cancer Immunotherapy Shows Promising Results Using Novel ‘Skin Patch’ Delivery System

News

Researchers have developed a promising technique to deliver cancer immunotherapy for melanoma. The method, using a skin patch implanted with microneedles, improved treatment efficiency in preclinical studies, raising hopes of improved clinical management ... Read more